

Cover Story
By Alexandria Carolan
At first glance, the United States Supreme Court’s 303 Creative LLC. v. Elenis ruling has nothing to do with health care—but, looking deeper, experts in oncology and law are sounding alarms that the decision can be used to discriminate against LGBTQ+ patients.
In Brief


Clinical Roundup


Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”















